Results 51 to 60 of about 3,535 (191)

Pharmacoeconomic feasibility of using Mirabegron in patients with overactive bladder

Качественная клиническая практика, 2021
Objective: to assess the clinical and economic efficiency and impact on the budget when using the drug Mirabegron in the treatment of an overactive bladder. Materials and methods. Study design — retrospective analysis of published data.
I. N. Dyakov, G. R. Kasyan
doaj   +1 more source

Dynamic phenotypic shifts and M2 receptor downregulation in bladder smooth muscle cells induced by mirabegron

Frontiers in Pharmacology
IntroductionMirabegron is available for treatment of overactive bladder (OAB). However, mechanisms underlying symptom improvements and long-term effects on bladder smooth muscle cells are uncertain.
A. E. Muderrisoglu, A. E. Muderrisoglu, A. Ciotkowska, B. Rutz, S. Hu, S. Qian, A. Tamalunas, C. G. Stief, M. Hennenberg   +8 more
doaj   +1 more source

Re: Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder

, 2016
EDITORIAL COMMENT Overactive bladder (OAB) is a highly prevalent disorder in the pediatric population. This event negatively affects and impairs children’s development. Antimuscarinics are the mainstay pharmacological management of OAB, but their side
Sinharib Çitgez, Citgez, Sinharib
core   +1 more source

The Benefits of Adding Non‐Antimuscarinic Pharmaceuticals in Combination With Beta‐3 Agonists for Overactive Bladder Treatment: A Systematic Review

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Antimuscarinics, as the current first‐line pharmacologic therapies for overactive bladder, exhibit low patient adherence and high rates of reported side effects. As a modern alternative pharmaceutical treatment, beta‐3 agonists, which relax the urinary bladder, may be more tolerable for patients, increasing adherence and ...
Felicity Smith, Charlotte Phelps, Christian Moro   +2 more
wiley   +1 more source

Phloroglucinol inhibits human ureteral contractions via activation of cAMP‐PKA pathway

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Phloroglucinol is used to treat renal colic, especially when non‐steroidal anti‐inflammatory drugs are contraindicated. This study aimed to clarify its mechanism by examining effects on human ureteral contractility and underlying signalling pathways. Experimental Approach Urinary levels of neurokinin A (NKA), substance P
Hanwen Liu, Ruize Xu, Zihan Guan, Lei Liu, Guangda Lv, Weibo Chen, Jiliang Wen, Jianing Liu, Jieke Yan, Fangxin Gong, Pan Xiao, Xiulin Zhang, Lei Zhang   +12 more
wiley   +1 more source

Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction

Obesity Reviews, EarlyView.
Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey, Irene Pomares‐Bri, Paula de Juan‐Maciá, Mariló Olivares‐Vicente, Enrique Barrajón‐Catalán, Vicente Micol, Enrique Roche, María Herranz‐López   +7 more
wiley   +1 more source

Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in female patients with refractory overactive bladder: a prospective study

Frontiers in Neuroscience
ObjectiveTo observe the efficacy and safety of pelvic floor magnetic stimulation (PFMS) combined with mirabegron in female patients with refractory overactive bladder (OAB) symptoms.Patients and methodsA total of 160 female patients with refractory OAB ...
Ping Liang, Qing-lai Tang, Tao Lin, Zheng-kun Tang, Fa-de Liu, Xing-zhu Zhou, Rong-zhen Tao   +6 more
doaj   +1 more source

Pioglitazone does not synergize with mirabegron to increase beige fat or further improve glucose metabolism

JCI Insight, 2021
BACKGROUND Beige and brown adipose tissue (BAT) are associated with improved metabolic homeostasis. We recently reported that the β3-adrenergic receptor agonist mirabegron induced beige adipose tissue in obese insulin-resistant subjects, and this was ...
Brian S. Finlin, Hasiyet Memetimin, Beibei Zhu, Amy L. Confides, Hemendra J. Vekaria, Riham H. El Khouli, Zachary R. Johnson, Philip M. Westgate, Jianzhong Chen, Andrew J. Morris, Patrick G. Sullivan, Esther E. Dupont-Versteegden, Philip A. Kern   +12 more
doaj   +1 more source

β3‐Adrenoceptor Agonists for Neurogenic Lower Urinary Tract Dysfunction: Evidence and Clinical Rationale for First‐Line Therapy

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1476-1478, November 2026.
ABSTRACT Aims To summarize current evidence on β3‐adrenoceptor agonists for managing neurogenic lower urinary tract dysfunction (NLUTD), focusing on their efficacy, safety, and clinical role in optimizing bladder storage and protecting upper tracts. Methods Evidence from randomized controlled trials, meta‐analyses, and observational studies in spinal ...
Sharon E. Fishberg, Rano Matta
wiley   +1 more source

The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication?

, 2015
FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOBACKGROUND. Alpha1 (α1)-blockers, 5-alpha reductase and phosphodiesterase type-5 inhibitors are pharmacological classes currently available for benign prostatic hyperplasia (BPH) treatment ...
Antunes, E., Calmasini, F.B., Alexandre, E.C., Monica, F.Z., Candido, T.Z., D'Ancona, C.A., Silva, D., De Nucci, G., De Oliveira, M.A.   +8 more
core   +1 more source